Sionna Therapeutics Reports Third Quarter 2025 Financial Results

Core Insights - Sionna Therapeutics has initiated the PreciSION CF Phase 2a proof-of-concept trial for NBD1 stabilizer SION-719 as an add-on to standard care for cystic fibrosis patients, with topline data expected in mid-2026 [1][3] - The company has also started a Phase 1 trial for SION-451 in dual combinations with other modulators, with results anticipated in mid-2026 [1][3] - Sionna maintains a strong cash position of approximately $325 million, which is expected to fund operations into 2028 [1][8] Pipeline Updates - The PreciSION CF Phase 2a trial will assess the safety, tolerability, and pharmacokinetics of SION-719, measuring CFTR function through sweat chloride levels [3] - A successful drug-drug interaction study confirmed that SION-719 can be safely combined with Trikafta, the current standard of care [3] - The Phase 1 trial for SION-451 will evaluate its efficacy in combination with SION-2222 and SION-109 in healthy volunteers [3] Business Highlights - In September 2025, Sionna appointed Caroline Stark Beer as Chief Business Officer, bringing over 20 years of life science industry experience [5] Financial Results - Research and development expenses for Q3 2025 were $16 million, down from $24.6 million in Q3 2024, primarily due to one-time charges from the previous year [6] - General and administrative expenses increased to $7.8 million in Q3 2025 from $3.4 million in Q3 2024, attributed to personnel costs and professional fees [7] - The net loss for Q3 2025 was $20.3 million, an improvement from a net loss of $25.4 million in Q3 2024 [7][14]